モレキュラーデバイスジャパン 東京本社 Official site

Organoids derived from iPS cells and tissue stem cells are expected to serve as advanced in vitro models for disease modeling and drug screening, as they mimic human tissue structure and function, thereby improving the clinical predictability of drug responses. However, challenges such as the complexity of sample preparation, reproducibility, and scalability hinder their practical application as a major screening method in drug discovery. To address this bottleneck in sample preparation, our product does not perform mechanical operations regularly; instead, AI machine learning automatically makes decisions based on monitoring results of the samples. Under a 24-hour operational environment, it appropriately conducts and manages medium exchanges and passaging, fully automating the complex workflow of the organoid culture process. As a result, we achieve significant reductions in costs and time, as well as a decrease in human error, while enhancing the productivity of the cell culture process in assays using iPS cells and organoids. *For detailed specifications, please refer to the PDF document or feel free to consult us.*

【Features】 ■ Automation of cell culture processes ■ Improvement of screening workflows ■ Development of assays with high reliability and reproducibility ■ Automated media exchange to reduce researchers' workload 【Additional Features】 ■ Expansion ports for integration with external devices to enhance workflow flexibility ■ Incubator offers two types of plate accommodation options tailored to workflows ■ HEPA filters to prevent contamination from entering the system ■ AI-assisted decision-making to create reliable and reproducible samples ■ Bulk media and on-deck media supporting various cell culture protocols ■ Integrated imager for monitoring cell culture over time *For detailed specifications, please refer to the PDF document or feel free to contact us.*

For more details, please refer to the PDF document or feel free to contact us.